Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials

Transfusion Medicine Reviews - Tập 36 - Trang 16-26 - 2022
Ryan Ruiyang Ling1, Jackie Jia Lin Sim1, Felicia Liying Tan1, Bee Choo Tai1,2, Nicholas Syn1, Sharavan Sadasiv Mucheli3, Bingwen Eugene Fan4, Saikat Mitra5, Kollengode Ramanathan1,6
1Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore
2Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore
3Department of Infectious Diseases, Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore
4Deparment of Haematology, Tan Tock Seng Hospital, Singapore
5Lyell McEwin Hospital, Adelaide, South Australia, Australia
6Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Singapore

Tài liệu tham khảo

Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032

Oliveira, 2021, ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida, PLoS One, 16, 10.1371/journal.pone.0249038

Lim, 2021, Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation, A Meta-analysis, Am J Respir Crit Care Med, 203, 54, 10.1164/rccm.202006-2405OC

Ling, 2021, Interleukin-6 receptor antagonists for severe coronavirus disease 2019: a meta-analysis of reconstructed individual patient data from randomised controlled trials, SSRN

Rochwerg, 2020, A living WHO guideline on drugs for covid-19, BMJ, 370, m3379

Mahase, 2021, Covid-19: regeneron's antibody combination cuts deaths in seronegative patients, trial finds, BMJ, 373, n1570, 10.1136/bmj.n1570

Arabi, 2016, Feasibility of using convalescent plasma immunotherapy for MERS-CoV Infection, Saudi Arabia, Emerg Infect Dis, 22, 1554, 10.3201/eid2209.151164

Mair-Jenkins, 2015, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, J Infect Dis, 211, 80, 10.1093/infdis/jiu396

Luke, 2006, Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?, Ann Intern Med, 145, 599, 10.7326/0003-4819-145-8-200610170-00139

Arciuolo, 2013, Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting-New York City, Clin Infect Dis 2017, 65, 1843, 10.1093/cid/cix639

Janiaud, 2021, Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA, 325, 1185, 10.1001/jama.2021.2747

Klassen, 2021, The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis, Mayo Clinic Proceedings, 96, 1262, 10.1016/j.mayocp.2021.02.008

Piechotta, 2021, Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review, Cochrane Database Syst Rev, 5

Avendaño-Solà, 2020, Convalescent plasma for COVID-19: a multicenter, randomized clinical trial, medRxiv

Bennett-Guerrero, 2021, Severe acute respiratory syndrome coronavirus 2 convalescent plasma versus standard plasma in coronavirus disease 2019 infected hospitalized patients in New York: a double-blind randomized trial, Crit Care Med, 10.1097/CCM.0000000000005066

Gharbharan, 2020, Convalescent plasma for COVID-19, A randomized clin trial, medRxiv

Li, 2020, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, 324, 460, 10.1001/jama.2020.10044

Libster, 2021, Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med, 384, 610, 10.1056/NEJMoa2033700

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ, 339, b2535, 10.1136/bmj.b2535

Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928

Guyatt, 2011, GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J Clin Epidemiol, 64, 383, 10.1016/j.jclinepi.2010.04.026

Clopper, 1934, The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial, Biometrika, 26, 404, 10.1093/biomet/26.4.404

DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2

Miller, 1978, The inverse of the freeman – Tukey double arcsine transformation, The American Statistician, 32, 138

Wan, 2014, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC Med Res Methodol, 14, 135, 10.1186/1471-2288-14-135

Balcells, 2021, Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial, PLoS Med, 18, 10.1371/journal.pmed.1003415

Hamdy Salman, 2020, Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study, Egypt J Anaesth, 36, 264, 10.1080/11101849.2020.1842087

Agarwal, 2020, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ, 371, m3939, 10.1136/bmj.m3939

AlQahtani, 2021, Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease, Sci Rep, 11, 9927, 10.1038/s41598-021-89444-5

Bajpai, 2020, Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial, medRxiv

Horby, 2021, Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, medRxiv

O'Donnell, 2021, A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19, medRxiv

Rasheed, 2020, The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq, Infez Med, 28, 357

Ray, 2020, Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial, medRxiv

Simonovich, 2021, A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med, 384, 619, 10.1056/NEJMoa2031304

Pouladzadeh, 2021, A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm, Intern Emerg Med, 1

Estcourt, 2021, The REMAP-CAP Investigators. convalescent plasma in critically ill patients with Covid-19, medRxiv

Sekine, 2021, Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial, Eur Respir J

The, 2021, C.-S.G. for The. Convalescent plasma for hospitalized patients with COVID-19 and the effect of plasma antibodies: a randomized controlled, open-label trial, medRxiv

Körper, 2021, Results of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients, J Clin Invest, 10.1172/JCI152264

Lünemann, 2015, Intravenous immunoglobulin in neurology–mode of action and clinical efficacy, Nat Rev Neurol, 11, 80, 10.1038/nrneurol.2014.253

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, 395, 1054

Seow, 2020, Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans, Nat Microbiol, 5, 1598, 10.1038/s41564-020-00813-8

Joyner, 2021, Convalescent plasma antibody levels and the risk of death from Covid-19, N Engl J Med, 384, 1015, 10.1056/NEJMoa2031893

Salazar, 2021, Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike Protein IgG, Am J Pathol, 191, 90, 10.1016/j.ajpath.2020.10.008

Hamilton, 2021, Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial, Int J Infect Dis, 109, 114, 10.1016/j.ijid.2021.06.034

Thompson, 2021, COVID-19, C. Consortium. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19, JAMA Oncol, 7, 1167, 10.1001/jamaoncol.2021.1799

2021, Summary Document for interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized or Approved in the United States

Thông tin
Thông tin xuất bản

Transfusion Medicine Reviews

Tập 36

16-26

Thông tin tác giả